HoldsUp

Mark Hyman, MD · 2025-08-13 · Mark Hyman (host), Simon Hill

The Food Industry Doesn't Want You to Know What's Actually Causing Chronic Disease

42 research-tied claims examined: 1 contradicted 1 overstated 7 context 31 supported 2 unverified

31

Supported by research

0:00:07Mark Hyman (host)supportedmoderate

US consumption of soybean oil has increased a thousandfold since 1900.

"Our consumption of soybean oil has increased a thousandfold since 1900." (said at 0:00:07)

Historical analysis of US food supply and economic disappearance data from 1909 to 1999 demonstrates that estimated per capita consumption of soybean oil increased more than 1,000-fold over the 20th century, driving substantial increases in the dietary availability of linoleic acid.

0:06:38Simon Hillsupportedhigh

Stearic acid, the predominant saturated fat in chocolate or cacao, does not seem to affect blood lipids.

"We talk about stearic acid, the most predominant saturated fat in chocolate or cacao that really doesn't seem to affect blood lipids." (said at 0:06:38)

Stearic acid (18:0) is the predominant saturated fatty acid in cocoa butter and chocolate. Extensive randomized controlled feeding trials and meta-analyses demonstrate that, unlike other long-chain saturated fatty acids such as palmitic (16:0) and myristic (14:0) acids, dietary stearic acid exhibits a relatively neutral effect on circulating total and LDL-cholesterol concentrations, behaving similarly to oleic acid or carbohydrates in its impact on the lipid profile.

0:11:46Simon Hillsupportedhigh

Approximately 75% of subjects dropped out of the Minnesota Coronary Experiment in the first year.

"75% of the subjects appear to drop out in the first year." (said at 0:11:46)

The claim is supported by the 2016 re-evaluation of recovered data from the Minnesota Coronary Experiment (PMID 27071971). Out of the 9,423 men and women randomized into the trial, only 2,355 participants were exposed to the study diets for one year or more. Due to high institutional turnover (discharges and dropouts) in the state mental hospitals and nursing home where the study was conducted, approximately 75% (7,068 of 9,423) of participants left the study before completing one year.

0:13:19Simon Hillsupportedmoderate

Meta-analyses of the longest, lowest-dropout randomized controlled trials replacing saturated fats with polyunsaturated fats show a reduction in cardiovascular events.

"when you look at the trials that are longest in duration with the least dropout, with a good intervention that probably doesn't have this confounding variable of trans fats, you do see a reduction in risk of cardiovascular events in these short-term kind of RCTs." (said at 0:13:19)

Meta-analyses of randomized controlled trials (RCTs) evaluating dietary fat modification demonstrate that replacing saturated fat with polyunsaturated fat (PUFA) or reducing saturated fat intake over long durations significantly reduces the risk of combined cardiovascular events and coronary heart disease (CHD). A systematic review and meta-analysis of RCTs (Mozaffarian et al., 2010, PMID 20351774) specifically evaluated trials where PUFA was increased in place of saturated fat for at least 1 year without major confounding interventions. It found a 19% reduction in CHD events (RR 0.81, 95% CI 0.70 to 0.95), and meta-regression confirmed that study duration was a key determinant of risk reduction, with trials of longer duration showing greater benefit. Similarly, the Cochrane Systematic Review (Hooper et al., 2020, PMID 32827219) assessed long-term RCTs (minimum duration 24 months) reducing saturated fat and found a 17% reduction in combined cardiovascular events (RR 0.83, 95% CI 0.70 to 0.98, moderate-quality evidence), with benefit tied to the degree of saturated fat reduction and serum cholesterol lowering.

0:13:46Simon Hillsupportedmoderate

About 40% of linoleic acid in the American diet comes from soybean oil alone.

"about 40% of linoleic acid in America comes from soybean oil alone" (said at 0:13:46)

Dietary availability and food-disappearance modeling studies of the US food supply (such as historical analyses by Blasbalg et al., 2011) demonstrate that soybean oil is the predominant dietary source of linoleic acid (LA) in the United States, contributing approximately 40% to 45% of total dietary linoleic acid intake following a >1000-fold increase in per capita soybean oil consumption over the 20th century.

0:14:03Simon Hillsupportedmoderate

Observational dietary survey data show that higher dietary intake of linoleic acid is associated with lower risk of coronary heart disease.

"when you look at that and you sort of quantify how much linoleic acid is in people's diets, they have lower risk of coronary heart disease compared to people with higher amounts of linoleic acid compared to those with lower." (said at 0:14:03)

Large systematic reviews and meta-analyses of prospective cohort studies consistently demonstrate that higher dietary intake of linoleic acid is associated with a significantly lower risk of coronary heart disease (CHD) events and CHD mortality compared to lower intake, especially when replacing saturated fatty acids.

0:14:38Simon Hillsupportedmoderate

Higher levels of linoleic acid in red blood cells or adipose tissue are associated with lower risk of coronary heart disease and lower total mortality.

"You see again here, you see lower risk of coronary heart disease, lower risk of total mortality with higher levels in both red blood cell or adipose tissue." (said at 0:14:38)

A large pooled analysis of 30 prospective cohort studies across 13 countries evaluating circulating and tissue biomarkers of linoleic acid (including adipose tissue, erythrocytes, plasma, and serum compartments) demonstrated that higher biomarker levels of linoleic acid were associated with lower risks of total cardiovascular disease, cardiovascular mortality, and ischemic stroke, as well as a trend toward lower coronary heart disease risk.

0:18:50Simon Hillsupportedhigh

Clinical trials show that overfeeding linoleic acid (omega-6) does not increase arachidonic acid levels in the body.

"there are clinical trials where you overfeed people omega-6s and linoleic acid and you measure the amount of arachidonic acid, which is the next omega-6 that's produced... And it doesn't go up. So the body seems to buffer it and hold it at a pretty steady state." (said at 0:18:50)

Clinical trials and systematic reviews demonstrate that increasing dietary linoleic acid (LA) does not increase arachidonic acid (AA) concentrations in circulating lipid pools (such as plasma or erythrocyte phospholipids). A systematic review of adult human intervention trials (Rett & Whelan, 2011) found that increasing dietary LA up to six-fold showed no significant correlation with changes in AA levels, reflecting tight physiological buffering and regulated conversion rates in adults.

0:19:20Simon Hillsupportedmoderate

High levels of omega-6 fatty acids compete for shared enzymes and reduce the conversion of plant-based ALA to EPA and DHA.

"these two pathways you mentioned, they share the enzymes. So if you have a whole lot of omega-6 running through that pathway and using a lot of these enzymes... you rely on the conversion to DHA and EPA. But if you have a lot of omega-6s in the diet, that conversion is even lower." (said at 0:19:20)

The omega-6 (linoleic acid) and omega-3 (alpha-linolenic acid, ALA) biosynthetic pathways utilize the same sequence of enzymes—primarily delta-6 desaturase, elongases, and delta-5 desaturase—to synthesize longer-chain polyunsaturated fatty acids. Stable isotope tracer studies in humans, animal feeding trials, and cellular models demonstrate that high dietary intakes or concentrations of omega-6 fatty acids compete for these shared enzymes, thereby reducing the rate and efficiency of ALA conversion to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

0:28:39Simon Hillsupportedhigh

Twelve-week clinical trials show that feeding a high-saturated-fat diet increases liver fat more than feeding a high-polyunsaturated-fat diet.

"I've been interested by some of these relatively short clinical trials, like 12-week studies looking at feeding people a lot of saturated fat or polyunsaturated fats... when you dial up saturated fats, you seem to increase liver fat more than when you dial up polyunsaturated fats." (said at 0:28:39)

Randomized clinical dietary intervention trials support the claim that increasing saturated fatty acid (SFA) intake increases liver fat accumulation to a significantly greater degree than increasing polyunsaturated fatty acid (PUFA) intake. In double-blind randomized controlled trials, hypercaloric overfeeding of SFA (e.g., palm oil) markedly increased intrahepatic lipid content (including a relative 50% increase in liver fat over 8 weeks), whereas overfeeding PUFA (e.g., sunflower oil) did not induce significant liver fat accumulation or liver enzyme elevation despite equal weight gain (PMID: 31369090, PMID: 24550191). While some study durations in this literature range from 7 to 8 weeks or up to 16 weeks under eucaloric conditions (PMID: 33381795), the clinical trial evidence robustly confirms that saturated fat promotes hepatic steatosis significantly more than polyunsaturated fat.

0:27:00Mark Hyman (host)supportedmoderate

Ultra-processed foods make up 60% of total caloric intake in the US diet.

"it's in all the ultra-processed food and that's 60% of our calories." (said at 0:27:00)

Nationally representative dietary data from the US National Health and Nutrition Examination Survey (NHANES) consistently demonstrate that ultra-processed foods account for approximately 57% to 60% of total daily energy intake among Americans. In an analysis of the NHANES 2009–2010 cycle (participants aged 1+ years), ultra-processed foods represented 57.9% of total calories. A trend analysis spanning 2001 to 2018 in US adults found consumption increased to 57.0% of total calories, with youth estimates frequently reaching or exceeding 65%. A figure of 60% is an accurate summary of these national estimates.

0:16:40Mark Hyman (host)supportedmoderate

The dietary ratio of omega-6 to omega-3 fatty acids in most Americans is approximately 20:1.

"Whereas, if you have a ratio that's, you know, 2:1, 1:1, 4:1, 5:1, that's okay. But most Americans are like 20:1 of the omega-6 to omega-3s." (said at 0:16:40)

The claim is supported by published nutritional literature. Multiple reviews and observational assessments note that the typical Western/American diet provides an omega-6 to omega-3 dietary ratio of approximately 15:1 to 20:1, primarily due to high consumption of linoleic acid from plant oils and low intake of marine omega-3 fatty acids.

0:27:10Mark Hyman (host)supportedmoderate

Soybean oil accounts for approximately 10% of total caloric intake in the United States.

"I mean, most people are not pouring soybean oil over their food, but it's 10% of our calories." (said at 0:27:10)

Analysis of 20th-century US dietary data (USDA food availability/economic disappearance data) indicates that per capita soybean oil consumption increased more than 1,000-fold between 1909 and 1999. In modern US diets, soybean oil has become the primary source of dietary fat and added polyunsaturated fatty acids, contributing approximately 7% to 10% of total daily caloric intake (and driving linoleic acid intake to >7% of total energy).

0:34:44Mark Hyman (host)supportedhigh

Commercial soybean oils are chemically extracted with hexane, sprayed with glyphosate, deodorized, and bleached during processing.

"So, they're they're extracted from soybeans, for example, with hexane, which is a toxin. They're sprayed with glyphosate, Roundup. They're deodorized. They're bleached. Uh, and they're chemically highly altered." (said at 0:34:44)

Standard commercial soybean oil production commonly utilizes glyphosate-tolerant soybean crops (which are sprayed with glyphosate during cultivation) and processes the seeds through solvent extraction using hexane, followed by industrial refining that includes neutralization, bleaching (using bleaching earths/adsorbents), and steam deodorization to produce refined, bleached, and deodorized (RBD) oil.

0:36:27Simon Hillsupportedmoderate

Higher levels of linoleic acid in red blood cells and adipose tissue are associated with lower risks of heart disease, cancer mortality, and all-cause mortality.

"And when I look at the linoleic acid seed oil consumption data, again coming back to red blood cell content and also adipose tissue, people with higher linoleic acid in their tissue have lower risk of heart disease, cancer mortality, and total mortality." (said at 0:36:27)

Large systematic reviews and pooled meta-analyses of prospective cohort studies demonstrate that higher biomarker levels of linoleic acid (measured in adipose tissue, red blood cells, or other blood compartments) are significantly associated with reduced risks of cardiovascular disease, cancer mortality, and all-cause mortality. A 2020 meta-analysis examining 65,411 participants with biomarker measurements found that each standard deviation increase in tissue/blood linoleic acid was associated with a 9% reduction in total mortality (RR 0.91, 95% CI 0.87–0.95), an 11% reduction in CVD mortality (RR 0.89, 95% CI 0.85–0.94), and a 9% reduction in cancer mortality (RR 0.91, 95% CI 0.84–0.98). A 2019 pooled consortium analysis of 30 prospective cohorts (68,659 participants) similarly confirmed that higher tissue and circulating linoleic acid levels are associated with significantly lower risks of total cardiovascular disease and cardiovascular mortality.

0:40:23Simon Hillsupportedmoderate

After age 50, muscle mass loss accelerates to 1% to 2% per year, totaling 10% to 14% loss per decade.

"and then by the age of 50, that can ramp up, so you you can be losing 1 to 2% of your muscle mass per year, right? So you could be losing 10-14% of your muscle mass per decade after the age of of 50." (said at 0:40:23)

The speaker's statement reflects standard estimates in musculoskeletal and aging research regarding the trajectory of sarcopenia. In inactive adults, muscle loss begins around age 30 at an average rate of 3% to 8% per decade and accelerates around age 50 to approximately 1% to 2% annually (equivalent to roughly 10% to 15% loss per decade), alongside a parallel decline in strength and resting metabolic rate.

0:40:46Simon Hillsupportedmoderate

After age 50, adults lose muscle strength and power at a faster rate per year than they lose muscle mass.

"From age 50, you're losing more strength per year than you are muscle mass, which is also really important: strength and power." (said at 0:40:46)

Published quantitative reviews and longitudinal studies demonstrate that muscle strength and power decline at a substantially faster annual rate than muscle mass in aging adults. While muscle mass decreases at approximately 0.5% to 1.0% per year with advancing age, muscle strength declines at roughly 2.5% to 4.0% per year, representing a rate of loss 2 to 5 times faster than the loss of mass (a distinction characterized clinically as dynapenia versus sarcopenia).

0:41:55Simon Hillsupportedhigh

Average daily protein intake among adults in the United States is approximately 1.2 grams per kilogram of body weight.

"but average protein intake is at about 1.2 grams per kilogram at the moment in in America, um, which could be a little bit further optimized" (said at 0:41:55)

Analysis of the National Health and Nutrition Examination Survey (NHANES) data confirms that average relative daily protein intake among adults in the United States is approximately 1.1 to 1.3 grams per kilogram of body weight per day. Specifically, Berryman et al. (2018) examined NHANES 2001–2014 data across 57,980 participants and found that relative protein intake among adult demographic groups averaged approximately 1.10 to 1.32 g/kg body weight per day (e.g., 1.10 ± 0.01 g/kg/d in adults ≥71 years, 1.18 ± 0.01 g/kg/d in non-Hispanic white and black adults >19 years, and 1.32 ± 0.02 g/kg/d in Asian and Hispanic adults >19 years). Therefore, the claim that average daily protein intake among US adults is approximately 1.2 g/kg is directly supported by nationally representative population data.

0:42:17Simon Hillsupportedmoderate

During aging and sedentary behavior, innervating motor units die off, accompanied by a selective reduction in Type II fast-twitch fibers and a relative increase in slow-twitch fibers.

"And unfortunately, what happens is that the when you're not stimulating the muscle, the kind of motor units, the nerves that go into the muscle that innervate them that allow us to contract to control, they they die off. And so something that I think is often not appreciated is that as we're aging, we're not just losing muscle mass, but the quality—we're losing quality muscle. And we get a shift from type II kind of fast-twitch fibers... And as we age, we get this reduction in the fast-twitch and relative increase in slow-twitch." (said at 0:42:17)

Published human physiological research and reviews confirm that aging and physical inactivity are associated with motor unit loss (denervation of motor neurons). This process disproportionately affects fast-twitch (Type II) muscle fibers, leading to selective Type II fiber atrophy and loss. Many surviving denervated fibers are subsequently reinnervated by slow-twitch (Type I) motor units (collateral sprouting), resulting in a relative shift and grouping toward slow-twitch fiber characteristics.

0:43:33Simon Hillsupportedlow

Master athletes who remain physically active in their 50s, 60s, 70s, and 80s can attenuate most age-related muscle loss.

"In order for us to combat this—and we see this, Mark, if you look at masters athletes, there's some studies... Older older athletes, right? So athletes that are in their 50s, 60s, 70s, you know, sometimes early 80s that have been physically active throughout their life, they can attenuate a lot of that muscle loss." (said at 0:43:33)

Cross-sectional studies and reviews demonstrate that master athletes aged 40 to 80+ who maintain high levels of chronic physical activity preserve significantly greater muscle mass, mid-thigh muscle area, and quadriceps strength compared to sedentary peers, effectively attenuating typical age-related muscle loss (sarcopenia). For example, Wroblewski et al. (2011) evaluated master athletes aged 40 to 81 and found that mid-thigh muscle area and lean mass did not decline across age groups, suggesting that much of the muscle loss observed in typical aging reflects disuse atrophy rather than intrinsic muscle aging alone. Similarly, Walsh et al. (2017) observed zero cases of sarcopenia among master athletes aged 40 to 70+ years. However, because these observational cross-sectional data cannot rule out healthy-user selection bias, the certainty of evidence is low.

0:49:38Simon Hillsupportedhigh

Studies demonstrate that increasing dietary protein intake without concurrent resistance training does not result in strength gains.

"There's a a beautiful study that looked at strength um and protein intake in two different contexts. So one was looking at as you dial up protein in the context of someone who's doing resistance training, and then the other is if you dial up protein and they're sedentary. What happens to strength? What you see is increasing protein without resistance training basically does nothing." (said at 0:49:38)

Dietary protein supplementation augments muscle strength and fat-free mass primarily when paired with progressive resistance exercise training. In the absence of resistance exercise or mechanical loading (such as in sedentary or physically inactive individuals), increasing dietary protein intake does not stimulate significant muscle hypertrophy or meaningful gains in muscle strength.

0:50:58Simon Hillsupportedhigh

During resistance training, the majority of strength and muscle-building benefits from protein are achieved at 1.2 g/kg, with minimal additional benefits gained between 1.2 and 1.6 g/kg.

"as you dial up protein, most of the benefit is is driven once you get to 1.2. There is a little bit further getting going from 1.2 to 1.6 g. It's kind of like squeezing the last few drops out of the towel." (said at 0:50:58)

Meta-analyses of randomized controlled trials examining protein intake during resistance training support the claim. A dose-response meta-analysis by Tagawa et al. (2020) demonstrated that the rate of lean mass accretion per 0.1 g/kg/day increase in protein intake is substantially steeper below 1.3 g/kg/day (0.39 kg increase) than above 1.3 g/kg/day (0.12 kg increase), confirming that the majority of muscle-building benefits occur at lower-to-moderate thresholds. Furthermore, landmark meta-analyses by Morton et al. (2018) and Tagawa et al. (2022) found that additional gains in fat-free mass and muscle strength plateau around 1.5 to 1.62 g/kg/day, beyond which no further significant training-induced benefits are observed.

0:52:17Simon Hillsupportedmoderate

Clinical trials by Hamilton Roschel and Alistair Monteyne comparing vegan and omnivorous diets at 1.6 to 2.0 g/kg protein intake showed no difference in muscle hypertrophy or strength gains over 10 to 12 weeks of resistance training.

"There's been a couple of clinical trials, Hamilton Roschel out of Brazil and then Alistair Monteyne and his group with Benjamin Wall that have actually looked at comparing omnivorous diets to vegan diets where all of the protein comes from plants... in these two studies that go for 10 and 12 weeks long where they're doing resistance training in healthy adults and they put the protein intake at 1.6 g per kilo or in Alistair Monteyne's it was more about 2 g per kilo which is pretty high. You do not see a difference in uh muscle size or strength gains throughout that 10 to 12 week period" (said at 0:52:17)

Both referenced clinical trials directly evaluated these parameters and found no significant differences between vegan and omnivorous diets. The 12-week trial led by Hamilton Roschel's group (Hevia-Larraín et al., 2021) compared habitual vegan and omnivorous young men undergoing resistance training at ~1.6 g/kg/day of protein and found identical gains in leg lean mass, muscle cross-sectional area, and 1RM strength. Similarly, the 10-week trial by Alistair Monteyne and Benjamin Wall's group (Monteyne et al., 2023) compared young adults on vegan vs. omnivorous diets at ~2.0 g/kg/day of protein and found comparable increases in lean mass, thigh muscle volume, muscle fiber cross-sectional area, and 1RM strength.

0:56:33Simon Hillsupportedhigh

A 9- to 10-day clinical study led by Luc van Loon and funded by Beef Checkoff found no significant difference in daily muscle protein synthesis rates between omnivorous and vegan diets at 1.1 to 1.2 g/kg protein intake in active older adults.

"Luc van Loon published a study who's a big protein researcher and this study was funded by Beef Checkoff... They had protein intake at 1.1 to 1.2 g per kilogram and they were using elderly um healthy adults that were active and looking at daily muscle protein synthesis rates and no significant difference between an omnivorous diet and a a vegan diet" (said at 0:56:33)

A randomized controlled crossover trial conducted by Luc van Loon's research group evaluated 34 active older adults (aged 72 ± 4 years) consuming a 10-day controlled vegan diet versus an isocaloric, isonitrogenous omnivorous diet. Integrated daily muscle protein synthesis (MPS) rates, measured using deuterated water, showed no statistically significant difference between the vegan (1.23 ± 0.04%/d) and omnivorous (1.29 ± 0.04%/d) diets (P = 0.2542).

0:48:21Simon Hillsupportedhigh

The Recommended Dietary Allowance (RDA) for protein of 0.8 g/kg was established based on nitrogen balance studies designed to determine minimum requirements to prevent deficiency, rather than to optimize muscle mass or function.

"GUEST1: They do these nitrogen balance studies and they were done a long, long time ago. But I'd say just at a very high level to explain that those studies are more looking at a requirement of protein— HOST: Like preventing protein deficiency. GUEST1: Not an optimization of protein, yeah." (said at 0:48:21)

The Recommended Dietary Allowance (RDA) for protein (0.8 g/kg body weight/day for healthy adults) was derived from meta-analyses of nitrogen balance studies designed to determine the minimum average protein intake necessary to achieve zero nitrogen balance (the estimated average requirement, or EAR) and meet the basic maintenance requirements of nearly all (97.5%) healthy individuals. These foundational studies evaluate the prevention of deficiency and basal nitrogen loss rather than the optimization of muscle mass, athletic performance, or functional outcomes.

0:54:50Mark Hyman (host)supportedmoderate

Older adults require at least 25 to 40 grams of protein per meal to reach the threshold that stimulates muscle protein synthesis.

"And they also said that you should have at least 25 to 40 g per meal in order to hit that that threshold of actually activating or switching on muscle protein synthesis or building muscle." (said at 0:54:50)

The claim is supported by clinical metabolic and observational evidence. Due to age-related anabolic resistance, older adults exhibit a reduced sensitivity of muscle protein synthesis (MPS) to low protein doses compared to younger adults. Dose-response studies show that older adults require higher relative protein intakes (~0.40 g/kg per meal, which translates to approximately 25 to 40 g of high-quality protein per meal) to maximally stimulate myofibrillar protein synthesis.

1:03:04Simon Hillsupportedmoderate

A study by Nicholas Burd comparing vegan and omnivorous diets with even versus uneven protein distribution (10% at breakfast, 30% at lunch, 60% at dinner vs. five even meals) found no difference in daily muscle protein synthesis rates across groups.

"and one of those studies that I mentioned there the Nicholas Burd um study not only compared a vegan to omnivorous looking at muscle protein synthesis but looked at two different distributions uneven and even. So they looked at one where they had five meals across the day, even distribution, and then the other was uneven. So they only had 10% of protein at breakfast, 30% at lunch, and 60% at dinner... And they didn't see it. And in fact, across both groups, even comparing to the same group, there was no difference in daily muscle protein synthesis rates, even in an uneven distribution." (said at 1:03:04)

A randomized controlled trial led by Nicholas Burd's research group evaluated 40 healthy young adults consuming either an omnivorous or vegan diet (1.1–1.2 g/kg/d protein) with either an unbalanced distribution (10%, 30%, and 60% of protein across three meals) or a balanced distribution (20% of protein across five eating occasions) during a 9-day resistance training protocol. Using deuterated water, the researchers measured daily myofibrillar protein synthesis rates and found no statistically significant differences between the omnivorous and vegan groups or between the even and uneven distribution patterns.

1:04:42Mark Hyman (host)supportedmoderate

The RDA for protein is the amount required to prevent protein deficiency rather than the amount needed for optimal health.

"So we need basically more protein, especially as we age, than the RDA, which is how much you need to not become protein deficient, which is not really a big problem." (said at 1:04:42)

The Recommended Dietary Allowance (RDA) for protein (0.8 g/kg/day for adults) is established to meet basic nutritional adequacy and prevent clinical deficiency (based on nitrogen equilibrium), rather than to maximize physiological function or optimal health. Published nutritional literature demonstrates that higher protein intakes—typically between 1.2 and 1.6 g/kg/day or higher—are required to optimize lean mass retention, muscle protein synthesis, healthy aging, and the mitigation of age-related sarcopenia.

1:08:24Mark Hyman (host)supportedvery low

In animal models, isolated and hydrolyzed soy protein produced significantly different effects, particularly regarding cancer outcomes, compared to whole soy foods.

"what he said was really interesting is when they studied in animal models giving isolated soy protein which is what or was done in these protein studies versus whole soy foods they're profoundly different effects particularly on cancer and that the basically soybean protein that's comes from you know um the as a byproduct of making soybean oil uh is is kind of a waste product and it's turned into these soy protein protein shakes or soy protein bars or soy protein whatever and that that hydrolyzed soy protein is chemically different than soy protein and linked to these cancer outcomes in in animal models." (said at 1:08:24)

Animal studies comparing purified soy protein isolate (SPI) with less-processed soy preparations (such as whole soy flour or soybean meal) have reported disparate effects on tumor development and growth in rodent models of estrogen-dependent breast cancer. For example, in estrogen-dependent mammary tumor models, isolated soy protein diets promoted tumor proliferation in a dose-dependent manner, whereas whole soy flour with equivalent genistein concentrations did not stimulate tumor growth. Similarly, transgenic mouse models showed increased mammary tumor incidence with isolated soy protein compared to complete protection when fed standard diets containing whole soybean meal. However, this evidence is derived entirely from rodent and xenograft models, which cannot be directly extrapolated to human dietary patterns or clinical cancer risk.

1:09:25Simon Hillsupportedmoderate

Cancer guidelines do not recommend avoiding whole soy foods for cancer prevention or patients with cancer, but do advise against taking soy isoflavone supplements.

"the guidelines now certainly are not telling people to to avoid soy foods for preventing cancer or whether they have cancer. But they do say, and I think this is important for people to know, not to take soy isoflavone supplements, which have become relatively popular. You'll find them all over the internet. So having that that very isolated high dose of isoflavones, there is no evidence right now to to recommend that for people. Um, and it could be deleterious for someone who has cancer." (said at 1:09:25)

The speaker's statement accurately reflects current oncology perspectives and clinical guidance regarding soy. Epidemiological evidence shows that dietary intake of whole soy foods is safe, not advised against for cancer prevention or cancer patients/survivors, and often associated with neutral or protective outcomes. Conversely, high-dose isolated soy isoflavone supplements are not recommended due to insufficient evidence of safety or benefit, along with concerns that concentrated phytoestrogens could exert stimulatory or adverse effects in hormone-sensitive cancers.

1:10:07Mark Hyman (host)supportedlow

Asian cohort studies show that populations consuming the highest amounts of whole soy foods have a lower risk of breast cancer.

"And you know, if you look at certain Asian cohort studies, they have a lower risk of breast cancer in the parts of the world where they consume the most... the most whole soy foods." (said at 1:10:07)

Observational evidence and meta-analyses of epidemiological studies in Asian populations show that higher intake of dietary soy foods is associated with a modest reduction in breast cancer risk. Meta-analyses of prospective cohort and case-control studies in Asian populations consistently report an inverse association (relative risks typically ranging from 0.71 to 0.81 for the highest versus lowest intake categories), an effect that is not consistently observed in Western cohorts with much lower baseline soy consumption. Because the available evidence consists primarily of observational cohorts and case-control studies with potential residual confounding, the overall certainty of evidence is low.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.